SCHEDULE: Avidity Partners Amends Scynexis Stake to 9.9%

Avidity Partners and related entities have filed an Amendment No. 7 to their Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scynexis, Inc. as of September 30, 2025.

Summary

• Avidity Partners Management LP, along with several related entities and Michael Gregory, collectively reported beneficial ownership of Scynexis, Inc. common stock.
• The filing, an Amendment No. 7 to Schedule 13G, indicates that as of September 30, 2025, Avidity Partners Management LP, its general partner Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, and Michael Gregory each beneficially own 4,281,284 shares, representing 9.9% of the class.
• Avidity Private Master Fund I LP also reported beneficial ownership of 4,516,757 shares, equating to 9.9% of the class.
• Avidity Master Fund LP reported beneficial ownership of 3,698,070 shares, representing 8.5% of the class.
• All reporting persons hold shared voting and shared dispositive power over their respective reported shares.
• The securities were not acquired or held for the purpose of changing or influencing control of Scynexis, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates continued significant institutional investment in Scynexis, Inc., suggesting confidence from a major investor. However, it is a routine disclosure and does not provide new operational or financial insights.

Positives

• The continued significant ownership by Avidity Partners and its affiliates indicates a sustained investment interest in Scynexis, Inc.
• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control, suggesting a passive investment stance.

Negatives

• The filing does not contain information that would typically be categorized as negative, as it is a disclosure of beneficial ownership rather than operational or financial performance.

Risks

• The filing itself does not detail specific risks related to Scynexis, Inc.'s operations or financial health, as it is a beneficial ownership report.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Scynexis, Inc.'s future performance or Avidity Partners' future investment intentions beyond the scope of this ownership report.

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. This filing shows continued significant institutional interest in Scynexis, Inc., which is common for publicly traded biotechnology or pharmaceutical companies.

Comparison to Industry Standards

• Institutional ownership at or near the 10% threshold, as seen with Avidity Partners' various entities in Scynexis, Inc., is a common occurrence across the biotechnology and pharmaceutical sectors. Such stakes are often held by specialized healthcare funds or diversified asset managers.
• For example, similar ownership levels are frequently observed in companies like Moderna (MRNA) or BioNTech (BNTX) where large institutional investors like BlackRock or Vanguard hold significant, passive stakes, often exceeding 5% or 10% through various funds.
• The 'passive' nature of this investment, as indicated by the 13G filing (not for control), aligns with typical institutional investment strategies in growth-oriented sectors like biotech, where investors seek long-term capital appreciation rather than direct operational influence.

Stakeholder Impact

• Shareholders: The continued significant stake by Avidity Partners may be viewed positively, signaling confidence from a major institutional investor. It also provides transparency regarding a large block of shares.
• Management: Awareness of a significant, passive institutional holder can influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing is a routine disclosure of beneficial ownership and does not contain new information regarding the company's operational performance, financial health, or strategic direction. While significant institutional ownership can be a positive signal, this amendment primarily updates the ownership percentage without providing a basis for a change in investment recommendation. Investors should hold their positions and await further operational or financial updates from Scynexis, Inc.

Keywords

Scynexis, Avidity Partners, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, SEC Filing